Neuronetics, Inc. 8-K

What Happened

• Neuronetics, Inc. (STIM) filed a Form 8‑K on March 17, 2026 reporting its financial results for the three months and twelve months ended December 31, 2025 (press release furnished as Exhibit 99.1). The company also released an investor presentation (Exhibit 99.2) and a separate press release announcing the CEO appointment (Exhibit 99.3).
• On March 12, 2026 the board appointed Daniel L. Reuvers, age 63, as President and Chief Executive Officer, with his employment expected to start on or about March 23, 2026. Reuvers is a 35+ year medtech executive, most recently CEO of Tactile Medical (May 2020–July 2024) and long‑time executive at Integra LifeScience (2009–2020).

Key Details

• Employment package: initial base salary $730,000 and discretionary annual cash bonus targeted at 100% of base salary.
• Equity award: 1,500,000 restricted stock units granted; 500,000 RSUs vest in substantially equal installments on each of the 1st, 2nd and 3rd anniversaries of his start date, subject to continued employment.
• Severance: if terminated without cause or for good reason, Reuvers is entitled to 12 months of base salary, a prorated target bonus and continued health coverage per the Severance Agreement.
• Documents: the earnings press release, investor presentation, and CEO appointment press release are filed as Exhibits 99.1–99.3; the Employment and Severance Agreements are referenced and incorporated by reference to Exhibits 10.47 and 10.48 of the company’s 2025 Form 10‑K.

Why It Matters

• Leadership change: naming an experienced medtech executive as CEO is a material corporate governance event that could influence Neuronetics’ strategic direction and investor expectations.
• Compensation alignment: the package mixes salary, a performance‑tied bonus target, and multi‑year equity vesting, signaling focus on multi‑year performance and retention.
• Next steps for investors: review the March 17, 2026 press release and presentation for the detailed financial results and management commentary, and monitor future filings for additional details on strategy or guidance under the new CEO.